Open AccessRole of MRI in staging of prostatic cancer based on PIRADS classification version 2
Author(s) -
O. Kamal,
Noha Mohammed Osman,
George Ezzat El Kess Yacoub,
Amr Ahmed Foly Abd El Baset
Publication year - 2022
Publication title -
international journal of health sciences (ijhs) (en línea)
Language(s) - English
Resource type - Journals
eISSN - 2550-6978
pISSN - 2550-696X
DOI - 10.53730/ijhs.v6ns3.5079
Subject(s) - medicine , prostate cancer , prostate , pathological , magnetic resonance imaging , radiology , cancer
Background; Prostate cancer is the second most common cancer in men worldwide. Two thirds of prostate cancer cases are diagnosed in the more developed regions of the world. Aim and objectives: The aim of this study was to evaluate the role of MRI imaging in staging of prostate cancer based on Prostate Imaging Reporting and Data System (PI-RADS) version 2. Subjects and methods: Thirty male patients were included in our study. They were referred to the department of Radiology, Minia Oncology Center with clinical and pathological diagnosis of prostatic carcinoma during the period extended from January 2019 to January 2021. Results: There was a statistically significant difference between PIRADs 4 and PIRADs 5 lesions as regard patients’ PSA, with higher values among PIRADs 5 cases. There was a statistically highly significant difference between PIRADs 4 and PIRADs 5 lesions as regard patients’ Gleason score, with higher values among PIRADs 5 cases. Conclusion: MRI examination of the prostate gland has a high specificity and sensitivity in primary diagnosis or staging over clinical assessment alone (PSA level and DRE), and other modalities like ultrasound.